Archimex expands deal with Ribonic, which could be worth up to $200M

Massachusetts, USA-based biotechnology group Archemix Corp has granted Japanese bio-venture firm Ribomic a worldwide, non-exclusive license to certain of its intellectual property rights to develop aptamers against multiple targets. Under the terms of the deal, Archemix will receive an upfront payment of $6.0 million. Ribomic has the option, upon payment of a further fee, to convert the licenses from non-exclusive to exclusive on a target-by-target basis. When the option is exercised, Archemix is eligible to receive milestone payments and a royalty on any marketed products developed under the agreement. Total milestone payments for the products combined could exceed $200.0 million. Other financial and business terms were not disclosed.